This study is exploring the safety of a treatment called MOON101 for people with peanut allergies. It's an open-label study, meaning everyone knows what they're getting. The research is done in three groups: adults, teens, and children. Each person gets both MOON101 (with peanut extract) and a placebo (without peanut extract) on their arms. The study looks at any bad reactions, called adverse events, and checks the highest safe dose each person can handle.

Participants will be in the study for about 73 days. They will have a screening visit, 5 treatment visits, follow-up calls, and a final check-up. The independent Data and Safety Monitoring Board (DSMB) will ensure everything is safe before moving to the next group of participants. About 40 people will join, split into the three age groups. Each person will be closely monitored, and the doses they get will gradually increase if they tolerate them well.

• Duration: The study lasts around 73 days.
• Visits: Participants have 5 treatment visits and follow-ups.
• Safety: Monitored by the DSMB to ensure safety.